Industrial Biotechnology 2012 - Bcnp-consultants.com

GoingPublic
3 Special March 2012 www.goingpublic.de
Sponsored by
Pflichtblatt an allen deutschen Wertpapierbörsen
GoingPublic
Das Kapitalmarktmagazin
S E C T I O N
Company profiles of the
Special “Industrial
Biotechnology”
SPECIAL
Magazin
Industrial Biotechnology
Vol. 3
Markets – Technologies – Financing – Investments

Service
“Company Profile” for Industrial
Biotechnology Champions
Dear Reader, On the following pages you will find a new
format of GoingPublic Magazin, especially developed for
this special, the so-called “Company Profile”. It is a tool
for companies to present themselves to the community.
The continuously growing number of players in the more
and more broadening field of industrial biotechnology
makes it hard to follow and to find the right cooperation
partners. Moreover, especially for small and medium
sized companies, it takes often a long time to connect
with the right industry partners looking for new technologies
being able to bridge gaps between chemistry and
biology and to find potential customers. This holds true
for the yet untypical industry partner besides the traditional
ones like food, feed and pharma where historically
biotechnology played a big role from the beginning.
This year’s presenters are a mixture of companies of all
kind. Not only small and medium sized enterprises present
themselves looking for strong partners in user industries.
It is also the other way round: Some of the big player can
be found in a row of this years “Company profiles”. In this
AMSilk has developed a unique process
for producing spider silk on an
industrial scale. Spider silk has
attract ed interest for thousands of
years, combining tensile strengths
rivaling that of steel while having the
elasti city of rubber on a weight-toweight
basis. In this combination,
silks reveal toughness two to three
times that of synthetic fibers like
Kevlar. Spider silk causes no inflammation
or allergic reaction. Spider
silk proteins can be assembled in all
three dimensions to build distinct
macroscopic structures like films,
spheres, fibers and nonwovens, etc.
56 Special “Industrial Biotechnology 2012”
AMSilk GmbH
Field of Activity
AMSilk produces Spidersilk TM Cleantech Biopolymers,
Biosteel TM fibers and innovative spider silk-based products.
Applications span several industries ranging from medical
devices to drug delivery and high-performance textiles.
Ownership Structure and Financing
Venture Capital (MIG Fonds) and private investors (AT Newtec)
Technology
Spider silk proteins are a versatile high-performance material
in medical device coatings, pharmaceutical applications and
technical films or fiber-based products. Spidersilk is made
through modern biotechnology methods. AMSilk provides
spider silk biopolymers, processed inter-stage materials and
final products to licensed partners.
Unique Selling Point
AMSilk is currently the only company with an industrial,
biotechnological process for spider silk production and processing.
Spidersilk is a uniquely stable, biocompatible
material, copied from nature’s blueprint.
way they show a strong interest in coming into contact
with innovative and flexible young entrepreneurial players.
It is not all about size like in the first days of the industry.
Everybody is looking for accelerating partnerships. Going-
Public offers here an international marketing platform for
quick access and decision, for contacts and impulses.
Company Profile Page
AMSilk 56
ARTES Biotechnology 57
Autodisplay Biotech 57
BRAIN 58
DIREVO Industrial Biotechnology 58
Emcid Biotech 59
Eucodis 59
evocatal 60
Evolva Holding 60
ORGANOBALANCE 61
Sanofi 61
SIRION BIOTECH 62
Wacker Chemie 62
Address
In the IZB
Am Klopferspitz 19
82152 Planegg-Martinsried
Germany
Telephone/Telefax
+49 (0)89 381 564 430 /
+49 (0)89 381 563 859
E-Mail
info@amsilk.com
Web Address
www.amsilk.com
Date of Incorporation
28. October 2008
Dr. Lin Römer (left), Head Research and Development
Axel Leimer, M.B.S., Managing Director

ARTES is a biotech company ope -
rating in the R&D field for development
of recombinant production cell
lines and processes based on microbial
platforms. Proprietary technologies
are applied in reliable processes
for innovative targets used in the
pharmaceutical and fine chemical
industry as well as for competitive
bio-similar products and vaccines.
Autodisplay Biotech GmbH is a
company commercializing its
proprietary expression platform for
the display of heterologous proteins
or peptides on the surface of E. coli.
This surface display system has
numerous advantages compared to
established surface technologies.
With these advantages Autodisplay
is a new platform technology in
biocatalysis, drug discovery, bioanalytics
and antibody development.
ARTES Biotechnology GmbH
Field of Activity
Contract R&D for development of recombinant production
cell lines and processes used in the field of bio -
pharmaceuticals, VLP based vaccines, enzymes and
biocatalyst processes.
Ownership Structure and Financing
Financed from cash-flow positive business.
Partners
Co-developments with m2p-labs GmbH, bitop AG,
Henkel AG & Co. KGaA, Q Chip ltd.
R&D projects for international pharmaceutical and nonpharmaceutical
companies.
Technology
Proprietary technology for expression and secretion in
yeast and bacteria (Hansenula, Arxula, E. coli, Bacillus).
VLP based platform for vaccine development.
Unique Selling Point
Engineering of host cell chaperone constitution targeting
difficult-to-express products in yeast.
Economic production processes based on low-cost raw
materials.
Membership in Networks/Associations
BioRiver, CliB 2021 , Dechema
Autodisplay Biotech GmbH
Field of Activity
Autodisplay Biotech is active in the field of biocatalysis,
drug discovery, bioanalytics (biochips, ELISA) and antibody
development (small protein drugs).
Ownership Structure and Financing
Private company funded by venture capital investors (Sirius
Venture, KfW) and several private investors
Partners
Industrial companies (e.g. Boehringer Ingelheim, Brain,
Phytowelt) and academic institutions (e.g. Dechema,
University of Münster)
Technology
The Autodisplay technology is a proprietary expression platform
for the display of heterologous proteins or peptides on
the surface of Escherichia coli (E. coli).
Unique Selling Point
Autodisplay technology as surface display technology with
numerous advantages compared to established surface
technologies like phage display.
Membership in Networks/Associations
CLIB 2021, BioRiver
Address
Elisabeth-Selbert-Straße 9
40764 Langenfeld
Germany
Telephone/Telefax
+49 (0)2173 27587-0 /
+49 (0)2173 27597-77
E-Mail
info@artes-biotechnology.com
Web Address
www.artes-biotechnology.com
Date of Incorporation/
Number of Employees
2002/20 employees
Dr. Michael Piontek, Managing Director
Address
Merowingerplatz 1a
40225 Düsseldorf
Germany
Telephone/Telefax
+49 (0)211 99459650
E-Mail
info@autodisplay-biotech.com
Web Address
www.autodisplay-biotech.com
Date of Incorporation/
Number of Employees
May 2008/6 employees
From left to right: Prof. Dr. Joachim Jose, CSO,
Dr. Ruth Maas, CEO, Dr. Gunter Festel, CFO,
Dr. Jürgen Schumacher, Advisory Board Member
Special “Industrial Biotechnology 2012” 57
Service

Service
BRAIN AG is one of Europe’s tech no -
logically leading industrial white biotechnology
companies. In strategic
co-operation projects with partners
and customers from the chemical
and pharmaceutical industries as
well as the cosmetics and food indus -
tries, BRAIN AG identifies and develops
innovative products and solu -
tions by harnessing nature’s yet
untapped microbial diversity. Active
product components are found in
BRAIN AG’s own “BioArchive”, one of
the most comprehensive of its kind.
Pictures: © Thomas Ott, Archiv BRAIN AG (above)
© Kristian Barthen, Archiv BRAIN AG (right)
At Direvo, we focus on the emerging
biomass conversion industry. We
identify bottlenecks and weaknesses
in current industrial processes in
this sector. We develop biologybased
solutions and implement
those for our partners and customers,
which include industrial
companies both large and small.
Our products are newly designed
enzymes and microorganisms of the
highest quality that provide easyto-implement,
cost-effective solu -
tions.
58 Special “Industrial Biotechnology 2012”
BRAIN AG
Field of Activity
Industrial Enzymes and BioCatalysts; BioActive Compounds
for Food and Cosmetics; Producer Strains and Designer
Micro-organisms
Ownership Structure and Financing
BRAIN AG is a private and independent research and development
corporation.
Partners
BRAIN’s strategic collaboration partners include: BASF,
Clariant, DSM, Evonik, Degussa, Genencor, Henkel,
Nutrinova, RWE, Sandoz, Bayer Schering, Südzucker and
Symrise, to name but a few
Technology
Metagenome®, ABEL®, LIL®, EvoSolution®, CompActives®,
BioCompActives®, BRAINzyme®
Unique Selling Point
Access to natures toolbox and its consequent use for
industrial applications.
Membership in Networks/Associations
BioDeutschland, IWBio, VCI, VBU, BioÖkonomierat, several
Boards of Technical Universities
DIREVO Industrial Biotechnology GmbH
Field of Activity
Direvo deploys its groundbreaking technology platform on
the huge opportunity currently being presented by the
clean energy, clean chemistry and biomass conversion
industries.
Ownership Structure and Financing
Privately owned. Investors include VC funds, banks and family
offices
Partners
Chemical & petrochemical industry, biofuels producers,
agricultural industry
Technology
Direvo's core technologies include molecular biology, genetics,
automation & high-throughput screening to develop tailormade
biological solutions.
Unique Selling Point
Direvo applies its profound expertise in bioengineering to
provide tailor-made, biology-based solutions for partners in
several sectors of the biomass conversion industry.
Membership in Networks/Associations
BIO, CLIB 2021, BIO River, Cleantec NRW, IWBIO, etc
Address
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
Telephone/Telefax
+49 (0)6251-9331-0
+49 (0)6251-9331-11
E-Mail
public@brain-biotech.de
Web Address
www.brain-biotech.de
Date of Incorporation/
Number of Employees
1993/99 employees
BRAIN Management Board: Dr. Holger Zinke (left),
Dr. Jürgen Eck
Address
Nattermannallee 1
50829 Cologne
Germany
Telephone/Telefax
+49 (0)221 47448-0 /
+49 (0)221 47448-111
E-Mail
info@direvo.com
Web Address
www.direvo.com
Date of Incorporation/
Number of Employees
2008/Currently 30+ Employees
Dr. Jörg Riesmeier, CEO (top left), Klaudija Milos (top right),
Dr. Albrecht Läufer (below left), Andreas Lischka (below right)

Emcid is developing a platform for
the identification, exploitation and
industrial use of unique natural
products as secondary metabolites
and enzymes from bryophytes,
mosses and other lower plants. The
company is targeting customers
from fine chemical industry. Within
this market it is focusing on agriculture,
cosmetics and food additives
as interesting sub-segments.
EUCODIS Bioscience is an applicationdriven
enzyme engineering and
manufacturing company with a
proven track record of providing
customized solutions. The portfolio
comprises over 50 enzymes includ -
ing innovative lipases, beta-lactamases,
catalases and others.
Our team works closely with our
customers to better understand
their individual needs providing
various custom protein & enzyme
services, ranging from strain and
process development, production
up-scale and downstream process -
ing to routine protein manu -
facturing up to the kg scale.
Emcid Biotech GmbH
Field of Activity
Development of own product candidates;
Contract research services in the area of Emcids core competencies
Ownership Structure and Financing
Privatly held company / revenues
Partners
Industrial and academic partners
Technology
Focus an moss-specific advantages,
Outstanding cultivation expertise,
Know-how in optimizing plant-cell-lines
Unique Selling Point
The combination of the biological features of mosses and
the scientific competence and experience of the team puts
Emcid into a unique position.
Membership in Networks/Associations
CLIB 2021
EUCODIS Bioscience GmbH
Field of Activity
EUCODIS delivers high-performance enzyme solutions for
highly specific applications in biopharma, fine chemicals
and cosmetics industry.
Ownership Structure and Financing
EUCODIS Bioscience is a private company, backed up by
institutional venture capital investors, founders, and private
investors.
Partners
EUCODIS has a branch office in Halle, Germany, and representations
in the UK and USA.
Technology
EUCODIS covers the whole spectrum of biocatalytic process
development up to industrial-scale manufacture of enzymes.
We provide our customers with a potent mutagenesis toolbox
which enables effective modification of target enzyme
properties.
Unique Selling Point
EUCODIS Bioscience is strongly focused on providing customized
solutions and services individually meeting our partners’
needs when it comes to manufacturing critical proteins.
Address
Hans-Bunte-Str.19
79108 Freiburg
Germany
Telephone/Telefax
+49 (0)761-881578-440
+49 (0)761-881578-441
E-Mail
info@emcid-biotech.de
Web Address
www.emcid-biotech.de
Date of Incorporation/
Number of Employees
2009/4 employees
Andreas Kranzusch (left), Managing Director
Dr. Gilbert Gorr, Managing Director
Address
Campus Vienna Biocenter 2
Viehmarktgasse 2a/2OG
1030 Vienna
Austria
Telephone/Telefax
+43 (0)1-8900804
+43 (0)1-8900804-11
E-Mail
office@eucodisbioscience.com
Web Address
www.eucodisbioscience.com
Date of Incorporation/
Number of Employees
2007/22 employees
Thomas Fischer,
Chief Executive Officer
Dr. Jan Modregger,
Head of Research
and Development
Special “Industrial Biotechnology 2012” 59
Service

Service
evocatal is a provider of enzyme technology
and biocatalytical processes.
The company offers a catalog of readyto-use
enzymes (evozymes) and chiral
building blocks but also offers the
customized development of exclusive
biocatalysts and chemical processes,
tailored to match the unique demands
of our customers. evozymes are
applied in API- and intermediate
synthesis, but also in consumer goods
industries, including the production
and refinement of textiles, adhesives,
detergents, nutrition and cosmetics.
Our enzymes and chiral building
blocks can be provided in every scale.
Pictures: Wiedemeier & Dahmen/evocatal
Evolva is leveraging its cutting edge
fermentation-based technology
platform to develop innovative,
high-value, and massively more
sustainable natural ingredients for
the Nutrition, Consumer Health and
Pharmaceutical industries. Evolva has
operations in Switzerland, Denmark,
India and the USA.
60 Special “Industrial Biotechnology 2012”
evocatal GmbH
Field of Activity
evocatal develops innovative solutions for biocatalysis
including a range of catalog products, development and
production services.
Ownership Structure and Financing
Privately held company, High-Tech Gründerfonds, Sirius Seed
Fonds, Business Angles
Partners
Evonik, RohnerChem, Henkel, Sartorius, Symrise, TU Delft,
Universität Hamburg/TUHH, Heinrich-Heine Universität
Düsseldorf, FZ Jülich, RWTH Aachen, ITB Stuttgart etc.
Technology
Biochemical and molecular engineering techniques.
Production strain development. Processes development for
fermentation and stereoselective synthesis.
Products/Services
evozymes®, evochemicals, evoglow®, Contract research (CRO)
and contract manufacturing (CMO) services.
Unique Selling Point
evocatal produces highly efficient biocatalysts for chemical
processes, and applies those to synthesize a range of pure
chiral fine chemicals.
Membership in Networks/Associations
Founding member of German IWBio e.V., CLIB 2021 e.V.,
BioRiver e.V., CleantechNRW
Evolva Holding SA
Field of Activity
Evolva is focusing on select Nutrition, Consumer
Healthcare and Pharma product sectors where market
growth has been constrained by scientific and supply chain
complexities – sectors where commercial success can,
there fore, be achieved through market expansion and is
not dependent upon the usual conquest of incumbents.
In both areas we have partnered projects as well as proprietary
programmes.
Ownership Structure and Financing
Evolva is listed on SIX Swiss Exchange in Zürich, ticker symbol
EVE. The company has a broad, international investor base.
Partners
Evolva is working with BASF, IFF and Roquette to develop
novel, efficient, and sustainable production routes for existing
high-value compounds. We are working with BASF and Roche
to develop novel compounds.
Technology
Proprietary yeast-based fermentation platform. Uniquely
allows Evolva to produce relatively sophisticated ingredients
for consumers and patients.
Unique Selling Point
Fermentation process differentiates Evolva from competition;
tangible product benefits (not commodities); technology platform
dramatically lowers COGS; simple supply chains, breadth
and depth of product pipeline create multiple “shots on goal”.
Address
Merowingerplatz 1a
40225 Düsseldorf
Germany
Telephone/Telefax
+49 (0)211 157 6095-0
+49 (0)211 157 6095-9
E-Mail
info@evocatal.com
Web Address
www.evocatal.com
Date of Incorporation/
Number of Employees
August 2006/23 employees
Dr. Christian Leggewie (CSO), Dr. Thorsten Eggert (CEO),
Dr. Michael Puls (CMO)
Address
Duggingerstrasse 23
4153 Reinach
Switzerland
Telephone/Telefax
+41 (0)61 485 20-00
+41 (0)61 485 20-01
E-Mail
info@evolva.com
Web Address
www.evolva.com
Date of Incorporation/
Number of Employees
June 2004/90 employees
Jutta Heim (CSO), Pascal Longchamp (CBO),
Jakob Dynnes Hansen (CFO) and Neil Goldsmith (CEO)

ORGANOBALANCE owns more than
8,000 proprietary yeast and lacto -
bacillus strains and explores this
valuable resource with a set of intelligent
OASSYS® bioassays to develop
new products, e.g. active ingredients.
ORGANOBALANCE furthermore uses
its unique expertise in yeast meta -
bolic engineering to design new
productions strains, for bulk and
fine chemicals and for proteins.
ORGANOBALANCE works in colla -
borations with corporate partners
and grants licenses for product
developments.
Sanofi, a global and diversified
healthcare leader, discovers,
develops and distributes thera -
peutic solutions focused on
patients’ needs. Sanofi has core
strengths in the field of healthcare
with seven growth platforms:
diabetes solutions, human vaccines,
innovative drugs, rare diseases,
consumer healthcare, emerging
markets and animal health.
ORGANOBALANCE GmbH
Field of Activity
ORGANOBALANCE provides research and development
partnership for new products in Food, Feed, Personal Care,
for the pharmaceutical industry and for the production of
fine chemicals.
Ownership Structure and Financing
Privately held company
Partners
Cooperation partners include BASF, General Mills, Lonza,
Sanofi Pasteur and undisclosed companies.
Technology
Company-owned culture collection; broad bioassay platform
(OASSYS®); yeast metabolic engineering; pilot-scale productions
and process developments
Unique Selling Point
Patentable natural strains and compounds for new product
developments; yeast production strains for industrial biotechnology
applications
Membership in Networks/Associations
DECHEMA e.V.; DIB/VCI; BIO Deutschland; IWBio; International
Probiotic Association; BPI e.V.
Sanofi
Field of Activity
Worldwide network of biotech manufacturing sites for
API’s, sterile medicines and devices. Cell culture technology
& manufacturing. Uniqueness in industrial scale solid
phase synthesis of biomolecules.
Ownership Structure and Financing
Sanofi is listed in Paris (EURONEXT: SAN) and New York
(NYSE: SNY)
Partners
Long tradition in biotech partnerships and cooperations with
enterprises and institutions. Sanofi Biotech is proactively
developing external partnerships to increase its biotechbased
portfolio.
Technology
Lab to industrial scale technologies acc. to cGMPs in up- and
downstream biotech processes, drug product aseptic filling,
analytical technology and others
Unique Selling Point
Comprehensive insulin/diabetes portfolio, faithful to insulin
tradition since 1923. Frankfurt, Germany, one of the
world’s largest insulin production sites. Genzyme (subsi -
diary), one of the world’s leading biotech companies,
specialized in rare diseases.
Address
Gustav-Meyer-Allee 25
13355 Berlin
Germany
Telephone/Telefax
+49 (0)30 46307-200
+49 (0)30 46307-210
E-Mail
info@organobalance.com
Web Address
www.organobalance.com
Date of Incorporation/
Number of Employees
July 2001/30 employees
Dr. Christine Lang, CEO
Address
Sanofi-Aventis Deutschland GmbH
Industrial Affairs, Site Frankfurt
Biotechnology, External Partner
Business Coordination, Jan Kloeppel
Industriepark Hoechst, D610
65926 Frankfurt
Germany
Telephone/Telefax
+49 (0)69 305 81368 /
+49 (0)69 305 942 588
E-Mail
Jan.Kloeppel@sanofi.com
Web Address
www.sanofi.de
Date of Incorporation
2004/105,000 Employees (Worldwide)
Dr. Uwe Wirth, Vice President Head of Biotechnology,
Industrial Chemistry & Biotechnology Affairs
Special “Industrial Biotechnology 2012” 61
Service

Service
SIRION BIOTECH specializes in viral
vector platforms and provides
sophisticated in vitro cell modeling.
This enables much improved com -
pound and target research for the
drug, the food & cosmetic indus -
tries. In addition, immortalizations
of primary cells to be used as in
vitro models are now easier to
perform. SIRION BIOTECH is able to
construct adenovirus serotype vectors
serving as the basis for novel
future vaccines with much improved
immunity.
WACKER is one of the world’s leading
and most research-intensive chemical
companies. Operating via five
business divisions, our team of
experts and local specialists focuses
on market needs and supports our
customers worldwide in developing
new products. With a 16,300-strong
workforce, 26 production sites in
Europe, Americas and Asia, and over
50 sales offices worldwide, we have
established a strong presence in all
key economic regions and growth
markets.
62 Special “Industrial Biotechnology 2012”
SIRION BIOTECH GmbH
Field of Activity
SIRION BIOTECH interacts with preclinical drug and other
compound discovery groups; from fee for service all the
way to milestone and royalty arrangements.
Ownership Structure and Financing
Creathor Venture, Bayern Kapital, HTGF, KfW
Partners
Sigma, InSphero, leading European Big Pharma
Technology
Patent protected recombinant viral vector platform with significant
know how in validating the right shRNA’s for optimal
results
Unique Selling Point
Services with more than 30 years of experience are freely
available from fee for service all the way to success based
payments
Membership in Networks/Associations
BioDeutschland, German Society for Cell Biology, FORPROJECT
Wacker Chemie AG
Field of Activity
Based on advanced biotech processes, the division WACKER
BIOSOLUTIONS offers tailored and innovative solutions and
products for the life-science sector, especially for the food
and pharma industry. Its biotech-based products include
pharmaceutical proteins, cyclodextrins and fermentationgrade
cysteine.
Ownership Structure and Financing
In November 2005, WACKER converted into a stock corporation
(AG) under German law. In 2006, the company successfully
launched its IPO.
Technology
– A proprietary ESETEC® E. coli secretion technology for the
production of pharma proteins.
– Metabolic engineering of bacteria for the production of
amino acids, above all L-cysteine.
– Production of cyclodextrins via proprietary CGTase-catalyzed
biotransformation of starch.
Unique Selling Point
– Highly efficient production of pharma proteins, due to the
secretion of correctly folded proteins into the culture supernatant.
– Fermentation-grade, vegetarian L-Cysteine products.
– Sustainable production of all three types of natural cyclodextrins.
Membership in Networks/Associations
Responsible Care®, Global Compact (GC)
Address
Am Klopferspitz 19
82152 Martinsried near Munich
Germany
Telephone/Telefax
+49 (0)89 700 961-999
E-Mail
info@sirion-biotech.de
Web Address
www.sirion-biotech.com
Date of Incorporation/
Number of Employees
2006/12 employees
Other
Your Cell Competence Center for all
your challenges in cell modelling
Dieter Lingelbach (COO) Dr. Christian Thirion (CTO)
Address
Hanns-Seidl-Platz 4
81737 München
Germany
Telephone/Telefax
+49 (0)89 6279-0
+49 (0)89 6279-1770
E-Mail
info.biosolutions@wacker.com
Web Address
www.wacker.com
Date of Incorporation/
Number of Employees
1914/16,314 employees (31/12/2010)
Dr. Gerhard Schmid,
President WACKER BIOSOLUTIONS

Contact media sales team
Expertise in Life Sciences
Special
Industrial Biotechnology 2012 (Vol. 3)
Publication date: February 25 th , 2012
Supplement
Healthcare 2012 (Vol. 6)
Publication date: March 31 st , 2012
Advertising close: March 19 th , 2012
Special Topic Life Science in
GoingPublic Magazin 7/2012
Publication date: June 30 th , 2012
Advertising close: June 18 th , 2012
Special edition
Biotechnology 2012 (Vol. 14)
Publication Date: September 15 th , 2012
Advertising close: September 3 rd , 2012
Supplement
Medical Technology 2012 (Vol. 10)
Publication date: November 14 th , 2012
Advertising close: November 2 nd , 2012
Daniela Gebauer Tel. +49 (0) 89-2000 339-13 gebauer@goingpublic.de
Katharina Meindl Tel. +49 (0) 89-2000 339-53 meindl@goingpublic.de
Karin Hofelich Tel. +49 (0) 89-2000 339-54
Tel. +49 (0) 177-422 52 89
karin.hofelich@goingpublic.de
Only GoingPublic Magazin’s Special “Industrial Biotechnology”
is published in English, all others in German.
Further info: www.goingpublic.de
GoingPublic´s
classic